immerhin hält dewb 23%.
Wednesday, 05/04/2005
NOXXON PHARMA AG DEMONSTRATES IN VIVO EFFICACY OF SPIEGELMERS® AGAINST
Berlin, Germany, May 4, 2005 -- NOXXON Pharma AG (NOXXON) today presented positive results from their cancer drug program at the Deutsche Bank’s 30th Annual Health Care Conference in Baltimore, Maryland. Defining a new milestone for NOXXON and its proprietary Spiegelmer® technology, the company demonstrated for the first time that
Spiegelmers® are highly effective in binding and neutralizing intracellular targets.
Thomas Klein, CEO of NOXXON, presented data on the inhibition of protein interactions inside the cell by Spiegelmers®. “The inclusion of intracellular targets further broadens the clinical utility of NOXXON’s Spiegelmer® technology” Mr. Klein stated. “This is another distinguishing factor, which, in combination with our molecules’ outstanding biostability, gives us a competitive advantage especially in comparison to antibodies.”
In a 22 day study with an aggressively growing pancreatic tumour cell line, NOXXON researchers showed that tumour growth in a Xenograft mouse model could be dramatically slowed by treatment with specially formulated NOX-A50, a Spiegelmer® developed against a transcription factor known to be involved in the development of many cancers. Animals that received a control Spiegelmer® exhibited uninhibited tumour growth.
Thomas Klein added further: " Our findings demonstrate that Spiegelmers® have the
potential to be powerful agents in the fight against cancer. The data also convincingly
reiterates the wide applicability of our technology.” NOXXON conducts R&D programs in various disease indications, focusing on targets in
metabolic diseases, inflammation, oncology, and cardiovascular disease.
About NOXXON Pharma AG, the next generation aptamer company:
Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.
URL: www.noxxon.net
E-Mail: tklein@noxxon.net
--------------------------------------------------
Source: NOXXON Pharma AG
Author: Thomas Klein, CEO
Also bei solchen Aussichten sollten die schon ihren 3stelligen millionenbetrag wert sein...
Also wenn man sich das Beteiligungsportfolio so anschaut dann scheint es noch so einige Perlen zu geben.
Wednesday, 05/04/2005
NOXXON PHARMA AG DEMONSTRATES IN VIVO EFFICACY OF SPIEGELMERS® AGAINST
Berlin, Germany, May 4, 2005 -- NOXXON Pharma AG (NOXXON) today presented positive results from their cancer drug program at the Deutsche Bank’s 30th Annual Health Care Conference in Baltimore, Maryland. Defining a new milestone for NOXXON and its proprietary Spiegelmer® technology, the company demonstrated for the first time that
Spiegelmers® are highly effective in binding and neutralizing intracellular targets.
Thomas Klein, CEO of NOXXON, presented data on the inhibition of protein interactions inside the cell by Spiegelmers®. “The inclusion of intracellular targets further broadens the clinical utility of NOXXON’s Spiegelmer® technology” Mr. Klein stated. “This is another distinguishing factor, which, in combination with our molecules’ outstanding biostability, gives us a competitive advantage especially in comparison to antibodies.”
In a 22 day study with an aggressively growing pancreatic tumour cell line, NOXXON researchers showed that tumour growth in a Xenograft mouse model could be dramatically slowed by treatment with specially formulated NOX-A50, a Spiegelmer® developed against a transcription factor known to be involved in the development of many cancers. Animals that received a control Spiegelmer® exhibited uninhibited tumour growth.
Thomas Klein added further: " Our findings demonstrate that Spiegelmers® have the
potential to be powerful agents in the fight against cancer. The data also convincingly
reiterates the wide applicability of our technology.” NOXXON conducts R&D programs in various disease indications, focusing on targets in
metabolic diseases, inflammation, oncology, and cardiovascular disease.
About NOXXON Pharma AG, the next generation aptamer company:
Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.
URL: www.noxxon.net
E-Mail: tklein@noxxon.net
--------------------------------------------------
Source: NOXXON Pharma AG
Author: Thomas Klein, CEO
Also bei solchen Aussichten sollten die schon ihren 3stelligen millionenbetrag wert sein...
Also wenn man sich das Beteiligungsportfolio so anschaut dann scheint es noch so einige Perlen zu geben.